Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03179800 · ClinicalTrials.gov registry record · NA

CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™

A NA study of Hypertension and Resistant Hypertension, sponsored by Vascular Dynamics.

Active
Registry status
NA
Development phase
300
Enrollment target
6
Study locations

NCT03179800 is a NA study of Hypertension and Resistant Hypertension that is active but no longer recruiting, run by Vascular Dynamics. The registered enrollment target is 300 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (91% lower). The trial reports 6 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03179800, a NA study of Hypertension and Resistant Hypertension, is active but no longer recruiting, sponsored by Vascular Dynamics.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
300 participants
Enrollment target
6
Study locations

Study Summary

The objective of this study is to evaluate the safety and effectiveness of the MobiusHD System in a prospective, randomized, double-blind, sham-controlled multi-center pivotal study.

Interventions

  • DEVICE MobiusHD
  • OTHER Sham Implantation

Study Locations (6)

Georgia

  • Emory University Hospital Midtown - Atlanta

Illinois

  • Southern Illinois University - Springfield

Indiana

  • St. Vincent Heart Center of Indiana - Indianapolis

Louisiana

  • Ochsner Medical Center - New Orleans

Ohio

  • The Carl & Edyth Lindner Center for Research & Education at The Christ Hospital - Cincinnati

Other

  • CHU Nancy Centre Coeur et Vaisseaux - Nancy

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2017-10-19
Est. Completion 2025-05
Phase NA

Sponsor

Vascular Dynamics

2 total trials

What the Registry Record Tells You About NCT03179800

The ClinicalTrials.gov registry entry for NCT03179800 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (91% lower). The listed sponsor is Vascular Dynamics, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Hypertension appearing as the primary indexed condition, and to 2 interventions - of which MobiusHD is the first listed.

NCT03179800 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Georgia, Illinois, Indiana.

Frequently Asked Questions

What is clinical trial NCT03179800 about?

NCT03179800 is a clinical study titled "CALM- 2 - Controlling and Lowering Blood Pressure With the MobiusHD™". The objective of this study is to evaluate the safety and effectiveness of the MobiusHD System in a prospective, randomized, double-blind, sham-controlled multi-center pivotal study.

What is the current status of trial NCT03179800?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2017-10-19. Estimated completion is 2025-05.

What conditions does trial NCT03179800 study?

This clinical trial studies the following conditions: Hypertension, Resistant Hypertension.

What interventions are being tested in trial NCT03179800?

The interventions under investigation include: MobiusHD (DEVICE), Sham Implantation (OTHER).

Who is sponsoring clinical trial NCT03179800?

This trial is sponsored by Vascular Dynamics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03179800 being conducted?

This trial has 6 study locations across Georgia, Illinois, Indiana, Louisiana, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.